The Medical Center of Delaware (MCD) CCOP Program has been organized to facilitate participation by community physicians in the Delaware region in CALGB clinical trials. The CCOP will utilize the comprehensive diagnostic and therapeutic facilities of the MCD and its affiliated hospitals. The participating oncologists and hematologists who utilize these institutions have expertise in all modalities of cancer care and the organization allows participation in protocol treatments at the research bases of CALGB through the auspices of the University of Maryland Cancer Center. The MCD has a long standing relationship with the CALGB and has participated in patient accrual since 1972. The MCD CCOP has an extensive catchment area which includes all of the State of Delaware and portions of Cecil County, MD and Salem County, NJ and Chester County, PA. This represents a patient population base in excess of one million with very large protocol entry potential. Protocol accrual to CALGB studies has been ongoing at the MCD despite the lack of financial support. In addition, protocol entries to NSABP and Children's Cancer Group show the willingness and experience of the various investigators to participate in clinical trials. It is anticipated that, given support for data management and other aspects of case accrual, the number of patients entered into study will increase.
The specific aim of the grant request is to provide funding to allow the MCD to continue to provide comprehensive care for patients in all stages of disease, allowing more patients to obtain State of Art treatment for cancer and remain in their communities while receiving this investigative therapy. The CCOP administration will consist of the principal investigators, project coordinators, and data managers. This administration will distribute data to participating investigators as well as maintain and monitor quality control. Flow sheets will be forwarded from the individual practices through the CCOP main office where they will be checked for completeness and then sent to the research base for appropriate data analysis and statistical support. Data distribution and attendance at the annual meetings will be used as mechanisms for further education, allowing dissemination of protocol information and research concepts. The overall impact of this grant will be to assure continuation and stimulate expansion of CALGB activities at the MCD and its affiliates. This mechanism will also allow for participation in cancer control research on a community-wide basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045418-02
Application #
3558605
Study Section
(SRC)
Project Start
1987-08-05
Project End
1990-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Christiana Care Health Services, Inc.
Department
Type
DUNS #
City
Newark
State
DE
Country
United States
Zip Code
19718
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7

Showing the most recent 10 out of 100 publications